These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21736504)

  • 1. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
    Lamm W; Vogl UM; Bojic M; Zielinski C; Klingler C; Kramer G; Schmidinger M
    Acta Oncol; 2012 Jan; 51(1):101-6. PubMed ID: 21736504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
    Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
    Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
    J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
    Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
    J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
    Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer.
    Schrader AJ; Seseke S; Keil C; Herrmann E; Goebell PJ; Weikert S; Steffens S; Bergmann L; Roigas J; Steiner T
    Eur Urol; 2014 Aug; 66(2):275-81. PubMed ID: 24012472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.
    Lee CK; Marschner IC; Simes RJ; Voysey M; Egleston B; Hudes G; de Souza P
    Clin Cancer Res; 2012 Jun; 18(11):3188-96. PubMed ID: 22472176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
    Paterson C; Jones RJ
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
    Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
    BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
    Gerullis H; Bergmann L; Maute L; Eimer C; Otto T
    Cancer Chemother Pharmacol; 2009 May; 63(6):1097-102. PubMed ID: 18818922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
    Patel SB; Stenehjem DD; Gill DM; Tantravahi SK; Agarwal AM; Hsu J; Vuong W; Pal SK; Agarwal N
    Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
    Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
    BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
    Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
    Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temsirolimus: a safety and efficacy review.
    Bukowski RM
    Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.